Plasma transforming growth factor β1 as a biomarker of psorioasis activity and treatment efficacy

Biomarkers

Volumn 8, Issue 5, 2003, Pages 437-443

  Flisiak, Iwona ^a   Porebski, Piotr ^a   Flisiak, Robert ^a   Chodynicka, Bozena ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Psoriasis; Psoriasis activity; Severity index; Transforming growth factor 1

Indexed keywords

BIOLOGICAL MARKER; DITHRANOL; SALICYLIC ACID; SULFUR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; INHIBITION KINETICS; KERATINOCYTE; MALE; OINTMENT; PROGNOSIS; PSORIASIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTHRALIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS; REGRESSION ANALYSIS; SALICYLIC ACID; SEVERITY OF ILLNESS INDEX; SULFUR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TREATMENT OUTCOME;

EID: 0344668500     PISSN: 1354750X     EISSN: None     Source Type: Journal    
DOI: 10.1080/13547500310001599061     Document Type: Article

References (22)

1. Blobe, G. C., Schiemann, W. P. and Lodish, H. F. 2000, Role of transforming growth factor β in human diseases. New England Journal of Medicine, 342, 1350-1358.
2. Borkowski, T. A., Letterio, J. J., Farr, A. G. and Udey, M. C. 1996, A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. Journal of Experimental Medicine, 184, 2417-2422.
3. 1 as an indicator of hepatic function impairment in liver cirrhosis. Cytokine, 12, 677-681.
4. 2 in plasma and scales from psoriatic lesions. Cytokine, 19, 121-125.
5. Fredriksson, T. and Pettersson, U. 1978, Severe psoriasis - oral therapy with a new retinoid. Dermatologica, 157, 238-244.
6. Furue, M., Kato, M., Nakamura, K., Nashiro, K., Kikuchi, K., Okochi, H., Miyazono, K. and Tamaki, K. 1997, Dysregulated expression of transforming growth factor beta and its type-I and type-II receptors in basal-cell carcinoma. International Journal of Cancer, 71, 505-509.
7. Gold, L. I., Jussila, T., Fusenig, N. E. and Stenback, F. 2000, TGF-beta isoforms are differentially expressed in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis. Journal of Pathology, 190, 579-588.
8. Grainger, D. J., Mosedale, D. E. and Metcalfe, J. C. 2000, TGF-β in blood: a complex problem. Cytokine and Growth Factor Review, 11, 133-145.
9. Kadunce, D. P. and Krueger, G. G. 1995, Pathogenesis of psoriasis. Dermatologic Clinics, 13, 723-737.
10. Kane, C. J., Knapp, A. M., Mansbridge, J. N. and Hanawalt, P. C. 1990, Transforming growth factor-beta 1 localization in normal and psoriatic epidermal keratinocytes in situ. Journal of Cell Physiology, 144, 144-150.
11. Kapp, A. 1993, The role of cytokines in the psoriatic inflammation. Journal of Dermatological Science, 5, 133-142.
12. Kondo, S., Hozumi, Y., Maejima, H. and Aso, K. 1992, Organ culture of psoriatic skin: effect of TGF-alpha and TGF-beta on epidermal structure in vitro. Archives of Dermatological Research, 284, 150-153.
13. Krueger, J. G., Krane, J. F., Carter, D. M. and Gottlieb, A. B. 1990, Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. Journal of Investigative Dermatology, 94 (6 supplement), 135-140.
14. Leivo, T., Leivo, I., Kariniemi, A. L., Keski-Oja, J. and Virtanen, I. 1998, Down-regulation of transforming growth factor-beta receptors I and II is seen in lesional but not non-lesional psoriatic epidermis. British Journal of Dermatology, 138, 57-62.
15. 3: the possible involvement of transforming growth factor-β induction. British Journal of Dermatology, 143, 1140-1148.
16. Powell, T. J., Ben-Bassat, H., Klein, B. Y., Chen, H., Shenoy, N., McCollough, J., Narog, B., Gazit, A., Harzstark, Z., Chaouat, M., Levitzki, R., Tang, C., McMahon, J., Shawver, L. and Levitzki, A. 1999, Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. British Journal of Dermatology, 141, 802-810.
17. Singer, A. J. and Clark, R. A. F. 1999, Cutaneous wound healing. New England Journal of Medicine, 341, 738-746.
18. Suomela, S., Kariniemi, A. L. and Snellman, E. 2001, Metalloelastase (MMP-12) and 92-kDa gelatinase (MMP-9) as well as their inhibitors, TIMP-1 and -3, are expressed in psoriatic lesions. Experimental Dermatology, 10, 175-183.
19. Thompson, M. and Feutren, G. 1997, Psoriasis Area and Severity Index. Basel: Novartis Pharma.
20. Wang, X. J., Greenhalgh, D. A., Bickenbach, J. R., Jiang, A., Bundman, D. S., Krieg, T., Derynck, R. and Roop, D. R. 1997, Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proceedings of the National Academy of Sciences of the USA, 94, 2386-2391.
21. Wataya-Kaneda, M., Hashimoto, K., Kato, M., Miyazono, K. and Yoshikawa, K. 1996, Differential localization of TGF-beta-precursor isotypes in psoriatic human skin. Journal of Dermatological Science, 11, 183-188.
22. Werner, S., Beer, H. D., Mauch, C., Luscher, B. and Werner, S. 2001, The Mad1 transcription factor is a novel target of activin and TGF-beta action in keratinocytes: possible role of Mad1 in wound healing and psoriasis. Oncogene, 8, 7494-7504.